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OBJECTIVES This study was designed to investigate the association between a common polymorphism
(Tyr402His, rs1061170) in the complement factor H (CFH) gene and risk of coronary heart
disease.
BACKGROUND The evidence that inflammation is an important mechanism in atherogenesis is growing.
C-reactive protein (CRP), complement factors, and complement regulatory factors have all
been linked to coronary heart disease. The CFH gene is an important regulator of the
alternative complement cascade. We investigated its association with coronary heart disease.
METHODS The study was embedded in the Rotterdam Study, a prospective population-based study
among men and women aged 55 years and over. A total of 5,520 participants without history
of coronary heart disease was genotyped for the Tyr402His polymorphism of the CFH gene.
Cox proportional hazards analysis was used to determine risk of myocardial infarction for
Tyr402His genotypes.
RESULTS Mean age among participants was 69.5 years (SD 9.1 years). The overall frequency of the His
allele was 36%; genotype frequencies were 41%, 45%, and 14% for TyrTyr, TyrHis, and
HisHis, respectively. During a mean follow-up period of 8.4 years, 226 myocardial infarctions
occurred. After adjustment for age, gender, established cardiovascular risk factors, and CRP
level, HisHis homozygotes had a hazard ratio of 1.77 (95% confidence interval 1.23 to 2.55)
for myocardial infarction. Total cholesterol level, diabetes mellitus, and smoking modified the
effect. The Tyr402His polymorphism was not associated with established cardiovascular risk
factors or CRP level.
CONCLUSIONS Our data suggest that the CFH gene determines susceptibility to myocardial infarction. This
finding underscores the importance of the alternative complement system in cardiovascular
disease. (J Am Coll Cardiol 2006;47:1568–75) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.076Cardiology Foundation
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anflammation has been shown to play an important role in
ardiovascular disease (1). Both complement factors and
omplement regulatory factors have been linked to athero-
clerosis (2). Complement inhibitor factor H (CFH) is a
lasma protein that is essential in the regulation of the
lternative complement pathway. Recently, several studies
ave found that the Tyr402His (rs1061170) polymorphism
n the CFH gene is strongly associated with age-related
acular degeneration, with relative risks of 2.5 to 7.4 for
omozygotes (3–7).
Complement inhibitor factor H has been suggested to
lay a part in complement inhibition in atherosclerotic
esions (8), and atherosclerosis has been implicated in the
evelopment of age-related macular degeneration (9).
From the Departments of *Epidemiology & Biostatistics and †Ophthalmology,
Internal Medicine, and §Clinical Genetics, Erasmus Medical Center, Rotterdam,
he Netherlands; ¶Department of Ophthalmogenetics, Netherlands Ophthalmic
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he Netherlands; and the Departments of Clinical Genetics and #Ophthalmology,
cademic Medical Center, Amsterdam, the Netherlands.c
Manuscript received September 15, 2005; revised manuscript received November
7, 2005, accepted November 28, 2005.herefore, the association between the CFH gene polymor-
hism and age-related macular degeneration may at least in
art be mediated by atherosclerosis. Research in coronary
rtery specimens suggests that interaction of CFH with
roteoglycans may be the mechanism by which complement
ctivation in the superficial layer of the coronary intima is
ontrolled (8). Consequently, we hypothesize that CFH
ay play a protective role in the development of coronary
eart disease.
Complement inhibitor factor H is encoded by a single
ene (HF1) on human chromosome 1q32. Several polymor-
hisms have been identified in the CFH gene, but their
otential influence on the levels of expression or on the
unction of CFH is uncertain (10). The Tyr402His poly-
orphism, representing a tyrosine-histidine change at
mino acid 402, is particularly interesting because this
hange is located within the cluster of positively charged
mino acids implicated in the binding of heparin and
-reactive protein (CRP) (11). Binding to these factors
ugments the ability of CFH to down-regulate the effect of
omplement. The substitution of a positively charged his-
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02 may alter the binding properties and have functional
mplications (10). These changes may alter CFH’s ability to
uppress excess complement activation, ultimately leading to
omplement-related damage to arterial walls and vessel
njury (4).
We set out to investigate the association between the
FH gene Tyr402His polymorphism and the risk of myo-
ardial infarction in the Rotterdam Study, a population-
ased cohort study in men and women age 55 years and
ver.
ETHODS
tudy population. The present study is part of the Rotter-
am Study, a population-based cohort study aimed at
ssessing the occurrence of and risk factors for chronic
iseases in the elderly. Objectives and methods of the
otterdam Study have been described in detail elsewhere
Abbreviations and Acronyms
CABG coronary artery bypass grafting
CFH  complement inhibitor factor H
CI  confidence interval
CRP  C-reactive protein
GP  general practitioner
HDL  high-density lipoprotein
PTCA  percutaneous transluminal coronary angioplastyFigure 1. Flow chart describing study population. CFH  comp12). The medical ethics committee of Erasmus Medical
enter, Rotterdam, approved the study. Participants gave
ritten informed consent and permission to retrieve infor-
ation from treating physicians.
Figure 1 shows a flow chart describing the study popu-
ation. The Rotterdam Study cohort includes 7,983 men
nd women aged 55 years and over (78% of the eligible
opulation), living in a well-defined suburb of the city of
otterdam, the Netherlands. Baseline data were collected
rom 1990 until 1993. A trained interviewer visited all
ubjects at home and collected information using a comput-
rized questionnaire. Additionally, established cardiovascu-
ar risk factors were measured at the research center in 7,129
articipants. Deoxyribonucleic acid (DNA) was available for
,571 subjects. Genotyping was successful in 6,345 partic-
pants. After excluding participants with a history of myo-
ardial infarction, percutaneous transluminal coronary an-
ioplasty (PTCA), or coronary artery bypass grafting
CABG) at baseline, 5,520 subjects were left for analysis.
enotyping. The participants were genotyped for the
yr402His (1277T  C) polymorphism of the CFH
ene. This polymorphism has been described under identifi-
ation number rs1061170 (13).
Deoxyribonucleic acid was extracted with proteinase K
nd sodium dodecyl sulfate digestion at 37°C overnight and
urified with phenol-chloroform extractions. The extracted
NA was then precipitated with NaCl at 4 mol/l and 2 vol
f cold absolute ethanol. DNA was solubilized in double-lement inhibitor factor H; DNA  deoxyribonucleic acid.
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CFH Gene Polymorphism and MI April 18, 2006:1568–75istilled water and stored at 20°C until used for DNA
mplification. Genotypes were determined in 2 ng genomic
NA with the Taqman allelic discrimination assay (Ap-
lied Biosystems, Foster City, California). Primer and
robe sequences were optimized by using the SNP assay-
y-design service of Applied Biosystems (14). Reactions
ere performed with the Taqman Prism 7900HT 384 wells
ormat.
ssessment of covariates. The information obtained dur-
ng the interview included current health status, medical
istory (including history of PTCA and CABG), drug use,
nd smoking status. At the research center, height and
eight were measured, and the body mass index was
alculated (weight [kg]/height [m2]). Blood pressure was
easured at the right brachial artery using a random-zero
phygmomanometer with the participant in sitting position.
iabetes mellitus was defined as the use of blood glucose
owering medication or a random or post-load serum
lucose level 11.1 mmol/l (15). C-reactive protein was
easured in serum, kept frozen at 20°C, using a nephe-
ometric method (Immage, Beckman Coulter, Fullerton,
alifornia). A 12-lead resting electrocardiogram (ECG) was
ecorded with an ACTA electrocardiograph (ESAOTE, Flo-
ence, Italy) at a sampling frequency of 500 Hz, and stored
igitally. All ECGs were processed by the Modular ECG
nalysis System (MEANS [16]) to obtain ECG measure-
ents and interpretations. Myocardial infarction found on
CG was based on criteria partly derived from the Minne-
ota code (17). A history of myocardial infarction was
onsidered present in case of a self-report of myocardial
nfarction confirmed by ECG or additional clinical infor-
ation, or the presence of an ECG characteristic of prior
yocardial infarction.
ollow-up procedure. Follow-up started at the baseline
xamination and lasted until January 1, 2002, for the present
tudy. Information on fatal and non-fatal myocardial infarc-
ions for the participants enlisted with the general practi-
ioners (GPs) working in the study district (85% of the
ohort) was obtained from these GPs. Computerized
ecords were sent to the Rotterdam Study data center
egularly. Subsequently, research assistants gathered infor-
ation about these events at the GP offices. All medical
ecords of the participants under the care of GPs outside the
tudy area (15% of the cohort) were checked annually for
ossible events. Letters and, in case of hospitalization,
ischarge reports from medical specialists were obtained.
ith respect to the vital status of participants, information
as also obtained regularly from the municipal health
uthorities in Rotterdam. After notification, cause and
ircumstances of death were established by questionnaire
rom the GPs.
Subsequently, two research physicians independently
oded all reported events according to the International
lassification of Diseases-10th edition (ICD-10) (18). Inase of disagreement, consensus was reached. Finally, a dedical expert in cardiovascular disease, whose judgment
as considered final, reviewed all events.
In identifying incident myocardial infarctions (ICD-10
ode I21), all available information, which included ECG,
ardiac enzyme levels, and the clinical judgment of the
reating specialist, was used. Persons with incident silent
yocardial infarctions were not identified.
ata analysis. Hardy-Weinberg equilibrium of the
yr402His polymorphism was tested using a chi-square
est. Differences in established cardiovascular risk factors for
he three genotypes were examined by using analysis of
ovariance, adjusting for age and gender. For age, this
nalysis was only adjusted for gender, and for gender, this
nalysis was only adjusted for age. C-reactive protein serum
evels were log-transformed because of their skewed
istribution.
Cox proportional hazards analysis was used to determine
he relative risks of myocardial infarction associated with
yr402His genotypes. The proportional hazards assump-
ion was tested by drawing log minus log plots of the
urvival function. In model 1, we adjusted for age and
ender; in model 2, we adjusted for age, gender, body mass
ndex, systolic blood pressure, diastolic blood pressure, total
holesterol, high-density lipoprotein (HDL) cholesterol,
moking, and diabetes mellitus; and in model 3, we adjusted
or the covariates in model 2 and additionally for CRP.
ge- and gender-adjusted survival curves were drawn show-
ng event-free survival until the occurrence of myocardial
nfarction. These curves were evaluated at the mean of the
ovariates (age and gender) in the 5,520 subjects used. For
ge, this was 69.1 years; for gender, this was 62% women.
First, analyses were performed in all participants. There-
fter, to examine effect modification, subgroup analyses
ere performed in strata of age, gender, body mass index,
ystolic blood pressure, diastolic blood pressure, total cho-
esterol, HDL cholesterol, smoking, diabetes mellitus, and
RP level. For continuous variables, participants were
ivided into subgroups according to the median values of
he variables. Similarly, models 1, 2, and 3, as described
bove, were used for these subgroup analyses. Interaction
erms were tested for the Tyr402His polymorphism and
ach of the covariates we stratified on, adjusting for age and
ender. For this purpose, the polymorphism was entered
nto the model as a continuous variable with three values,
amely homozygotes for the common allele (value 0),
eterozygotes (value 1), and homozygotes for the rare allele
value 2).
Values for cardiovascular covariates were missing in 4%
f participants, except for CRP, which was missing in 7%.
issing values were handled by single imputation using the
xpectation-maximization algorithm based on age, gender,
ody mass index, systolic blood pressure, diastolic blood
ressure, total cholesterol, HDL cholesterol, smoking, dia-
etes mellitus, and CRP.
All analyses were performed using SPSS 11.0 for Win-ows (SPSS Inc., Cary, North Carolina).
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enotype distributions were in Hardy-Weinberg equilib-
ium. The overall frequency of the His allele was 36%;
enotype frequencies were 41%, 45%, and 14% for TyrTyr,
yrHis, and HisHis, respectively. Table 1 shows baseline
haracteristics of all participants in which genotyping was
uccessful. None of the studied characteristics, namely age,
ender, body mass index, systolic and diastolic blood pres-
ure, hypertension, total and HDL cholesterol, diabetes
ellitus, smoking, and CRP, were associated with
yr402His genotype.
During a mean of 8.4 (SD 2.7) years of follow-up, 226
ases of myocardial infarction occurred among participants
ho had no history of myocardial infarction, CABG, or
TCA at baseline. Follow-up information on myocardial
nfarction was complete for 5,237 of 5,520 participants used
or the analysis (94.9%). The potential number of person-
ears that could have been contributed by these 5,520
articipants until myocardial infarction, death, or the end of
able 1. Baseline Characteristics of the Total Population
Total (n  6,345)
ge (yrs) 69.5  9.1
omen (%) 60.0
ody mass index (kg/m2) 26.3  3.7
ystolic blood pressure (mm Hg) 139  22
iastolic blood pressure (mm Hg) 74  11
otal cholesterol (mmol/l) 6.6  1.2
DL cholesterol (mmol/l) 1.3  0.4
iabetes mellitus (%) 10.4
mokers (%)
Never 35.5
Current 22.7
Former 41.8
istory of hypertension (%) 34.3
-reactive protein (mg/l)* 1.87 (0.90–3.67)
ategorical variables are expressed as percentage. Values of continuous variables are
xpressed as mean  standard deviation for total. *Median and interquartile range
ecause of skewed distribution.
HDL  high-density lipoprotein.
Table 2. Hazard Ratios for Myocardial Infarct
Genotype Events/Subjects Mod
All
TyrTyr 81/2,251 1.00 (refe
TyrHis 99/2,509 1.14 (0.8
HisHis 46/760 1.72 (1.2
Men
TyrTyr 46/863 1.00 (refe
TyrHis 58/924 1.22 (0.8
HisHis 28/293 1.82 (1.1
Women
TyrTyr 35/1,388 1.00 (refe
TyrHis 41/1,585 1.03 (0.6
HisHis 18/467 1.54 (0.8
Model 1: adjusted for age and gender; model 2: adjusted for a
pressure, total cholesterol, high-density lipoprotein choleste
gender, body mass index, systolic blood pressure, diastolic blood pre
smoking, diabetes mellitus, and C-reactive protein.he follow-up period was 46,516.7. We were able to observe
6,173.5 person-years (99.3%) until the date that a partic-
pant was last know to be alive, myocardial infarction, death,
r the end of the follow-up period.
In Table 2, hazard ratios for myocardial infarction are
isplayed according to Tyr402His genotype. In reference to
ild type, heterozygotes had a 14% to 16% increased risk of
yocardial infarction, but this did not reach statistical
ignificance. After adjustment for age and gender (model 1),
isHis homozygotes had a hazard ratio of 1.72 (95%
onfidence interval [CI] 1.20 to 2.47) for developing myo-
ardial infarction. After additional adjustment for estab-
ished cardiovascular risk factors (model 2), the hazard ratio
lightly increased to 1.77 (95% CI 1.23 to 2.54). Further
djustment for CRP (model 3) did not change the estimate.
hen we repeated the analysis without excluding partici-
ants with coronary heart disease at baseline, the results did
ot change materially.
The hazard ratios in men and women are also displayed
n Table 2. After full adjustment (model 3), male HisHis
omozygotes had a hazard ratio of 1.95 (95% CI 1.21 to
.13) for developing myocardial infarction, whereas for
emale HisHis homozygotes this was 1.54 (95% CI 0.87 to
.73). The latter value may not have reached statistical
ignificance due to lack of power in women.
Event-free survival until the occurrence of myocardial
nfarction is displayed in Figure 2. Homozygotes for the rare
is allele had a significantly lower event-free survival.
Figure 3 displays the effects of potential modifiers of the
ssociation between Tyr402His and myocardial infarction
n an age- and gender-adjusted subgroup analysis. Overall,
isk of myocardial infarction was increased for HisHis
omozygotes in all subgroups. The risk of myocardial
nfarction was considerably higher in participants with total
holesterol levels above the median versus those with levels
elow the median (p for interaction 0.05), in subjects with
iabetes versus subjects without diabetes (p for interaction
ccording to Tyr402His Genotype
zard Ratio (95% Confidence Interval)
Model 2 Model 3
) 1.00 (reference) 1.00 (reference)
3) 1.16 (0.86–1.55) 1.16 (0.86–1.55)
7) 1.77 (1.23–2.54) 1.77 (1.23–2.55)
) 1.00 (reference) 1.00 (reference)
9) 1.25 (0.85–1.84) 1.25 (0.84–1.84)
6) 1.94 (1.21–3.12) 1.95 (1.21–3.13)
) 1.00 (reference) 1.00 (reference)
2) 1.02 (0.65–1.60) 1.02 (0.65–1.61)
1) 1.53 (0.86–2.70) 1.54 (0.87–2.73)
der, body mass index, systolic blood pressure, diastolic blood
oking, and diabetes mellitus; model 3: adjusted for age,ion A
Ha
el 1
rence
5–1.5
0–2.4
rence
3–1.7
6–2.9
rence
6–1.6
7–2.7
ge, gen
rol, smssure, total cholesterol, high-density lipoprotein cholesterol,
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CFH Gene Polymorphism and MI April 18, 2006:1568–75.02), and in current smokers versus former and never
mokers (p for interaction 0.06). The risk for subjects with
bove-median CRP levels was somewhat higher, but the
nteraction did not reach statistical significance (p for
nteraction 0.31). The remaining age- and gender-adjusted
nteraction coefficients of the Tyr402His polymorphism and
he covariates upon which we stratified were not significant.
ubgroup analysis with additional adjustment for age, gen-
er, body mass index, systolic blood pressure, diastolic blood
ressure, total cholesterol, HDL cholesterol, smoking, dia-
etes mellitus, and CRP did not materially alter the results.
ISCUSSION
n the present study, the CFH gene Tyr402His polymor-
hism was associated with an increased risk of myocardial
nfarction in participants without a history of coronary heart
isease. Total cholesterol levels, diabetes mellitus, and
moking modified the effect. The CFH gene Tyr402His
olymorphism was not associated with established cardio-
ascular risk factors, or with serum CRP levels. Adjustment
or these factors did not essentially alter the risk of myocar-
ial infarction. This study was performed within a large,
rospective, population-based cohort, with lengthy
ollow-up time and a considerable number of incident
yocardial infarction cases available for analysis.
Inflammation has been recognized as an important mech-
nism in coronary heart disease and other manifestations of
therosclerosis (1). The complement system contributes to
nflammation in the arterial intima, and thus may exert
nfavorable effects on atherosclerosis (2). The complement
ystem contains several plasma and membrane-associated
roteins that are organized in three activation pathways: the
Figure 2. Age- and gender-adjusted event-flassical, the lectin, and the alternative pathway. Comple- gent inhibitor factor H is a plasma protein that plays an
mportant part in the inhibition of the alternative pathway;
t restricts the action of complement to activating surfaces
y binding to C3b, accelerating the decay of the alternative
athway C3-convertase (C3bBb) and acting as a cofactor for
he factor-I–mediated proteolytic inactivation of C3b (10).
his mechanism allows for activation of the early comple-
ent cascade by opsonization and may thereby play a
rotective role; however, complement activation is limited
o the C3 level, and does not lead to full complement
ctivation with cell lysis and ensuing inflammation (8).
Several studies provide evidence for a regulatory role of
FH in the development of atherosclerosis. Complement
nhibitor factor H has been found to be associated with
everity of coronary luminal narrowing in patients receiving
oronary angiography (19). In a study of human atheroscle-
otic lesions, CFH was observed in a large proportion of the
esions (20). Experimental observations have raised the
ossibility that interaction between proteoglycans and
FH, which co-localize in the superficial layer of the
ntima, may inhibit complement activation in the superficial
ayer of the arterial intima (8). Furthermore, it has been
hown that CFH binds to CRP, which may help to inhibit
he CRP-dependent alternative complement activation
athway induced by damaged tissue (21,22). C-reactive
rotein has been found to be associated with both coronary
eart disease and age-related macular degeneration (23,24).
Complement inhibitor factor H is encoded by a single
ene (HF1) that is part of the regulator of complement
ctivation gene cluster on human chromosome 1q32 that
ncodes several regulatory proteins of the complement
ystem. Several polymorphisms have been identified in this
rvival until incident myocardial infarction.ene, but their potential influence on the levels of expression
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April 18, 2006:1568–75 CFH Gene Polymorphism and MIr on the function of CFH is uncertain (10). The
yr402His polymorphism is located within the cluster of
ositively charged amino acids implicated in the binding of
eparin and CRP. Binding to either of these partners
igure 3. Age- and gender-adjusted hazard ratios for myocardial infarctio
alues for continuous variables. BMI  body mass index; CRP  C-reacncreases the affinity of CFH for the complement protein h3b (22,25), augmenting its ability to down-regulate com-
lement’s effect. The substitution of a positively charged
istidine for a non-charged hydrophobic tyrosine in posi-
ion 402 may alter the binding properties and consequently
rding to Tyr402His genotype in subgroups, created according to median
rotein; HDL  high-density lipoprotein.n accoave functional implications.
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CFH Gene Polymorphism and MI April 18, 2006:1568–75Recently, an association of the Tyr402His polymorphism
ith risk of vascular events could not be demonstrated in a
ested case-control study within the Physicians’ Health
tudy (26). The authors report that they had the ability to
etect, with 80% power, at an alpha of 0.05, a risk ratio of
1.35 for the His variant for vascular events (myocardial
nfarction, ischemic stroke, deep venous thrombosis/
ulmonary embolism, n  685). Therefore, and also based
n the effect estimates and CIs found, as stated by the
uthors, a modest risk of vascular events associated with the
enotypes tested could not be fully excluded.
Several aspects of the present study warrant further
onsideration. One limitation is that it remains to be
nvestigated whether the Tyr402His variant is the true
nderlying variant and does not represent a marker in
omplete or partial linkage disequilibrium, either within the
FH gene itself or in flanking genes. Still, several argu-
ents support the involvement of the CFH gene and in
articular the Tyr402His polymorphism in explaining the
isk of myocardial infarction. First, the CFH gene is a
redible candidate because several studies provide evidence
or a regulatory role of CFH in the development of
therosclerosis. Second, the substitution of a positively
harged histidine for a non-charged hydrophobic tyrosine
heoretically has functional implications for the CFH pro-
ein. Finally, haplotype reconstruction has implicated this
olymorphism in relation to complement-mediated patho-
enesis of age-related macular degeneration (3,7). Despite
hese arguments, further research is warranted to disclose
hether the Tyr402His variant is truly involved in explain-
ng the risk of coronary heart disease. While our results are
romising, the potential of other variants in the CFH gene
o influence coronary heart disease risk should be further
nvestigated.
Another limitation of the study is found in the follow-up.
e performed a thorough follow-up procedure with regard
o recognizable myocardial infarction, attaining 94.9% com-
leteness. However, our follow-up did not contain incident
ilent myocardial infarction, although patients with silent
yocardial infarction are in many aspects similar to those
ith recognized myocardial infarction (27). The result is
hat incident silent myocardial infarction cases were missed
nd have been considered as non-cases in the analysis.
ecause this is non-differential misclassification of the
utcome, it should not have influenced our results. We
resent relative risks, which remain the same. Only the risk
ifference between the genotypes could have changed due to
his type of misclassification (28).
The effect of the Tyr402His polymorphism on risk of
yocardial infarction was modified by high total cholesterol
evels, presence of diabetes mellitus, and smoking. These
actors all have been shown to be pathogens in vessel
nflammation (1,29,30). When the alternative complement
athway is activated by such pathogens, it is plausible that
ubjects with a genetic susceptibility in CFH such as the
yr402His variant respond with a reduced complementnhibition and thereby increase their risk of vessel damage,
oronary atherosclerosis, and, subsequently, myocardial in-
arction. Because the Tyr402His polymorphism is located
ithin the cluster of amino acids implicated in the binding
f CRP, we also expected CRP level to modify the risk of
yocardial infarction. Although the risk was slightly higher
n participants with CRP levels above the median, the
nteraction with CRP was not significant.
In conclusion, we have found an association between the
FH gene Tyr402His polymorphism and myocardial in-
arction. This suggests that CFH may play an important
ole in atherosclerosis, and underscores the importance of
he alternative complement system in cardiovascular disease.
eprint requests and correspondence: Dr. Jacqueline C. M.
itteman, Erasmus Medical Center, Department of Epidemiol-
gy & Biostatistics, P.O. Box 1738, 3000 DR Rotterdam, the
etherlands. E-mail: j.witteman@erasmusmc.nl.
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